Home » Topics » Regulatory » EMA

EMA
RSS

NTP-42 receives E.U., U.S. orphan designations for pulmonary arterial hypertension

March 8, 2018

Vocimagene amiretrorepvec/5-fluorocytosine granted E.U. orphan designation for glioma

March 8, 2018

EMA accepts regulatory submission for Forxiga in adults with type 1 diabetes

March 7, 2018

Gene therapy from Meiragtx receives European PRIME disgnation

March 5, 2018

EMA grants orphan drug designation to MTD-119 for hepatocellular carcinoma

March 1, 2018

EMA gives accelerated assessment to Shire's lanadelumab

Feb. 28, 2018

EMA grants orphan drug designation to cannabidiol for tuberous sclerosis

Feb. 28, 2018

EMA committee recommends change to marketing authorization terms for Feraccru

Feb. 26, 2018

BioCryst's Alpivab recommended for approval in E.U. for uncomplicated influenza

Feb. 26, 2018

Amglidia recommended for E.U. approval for neonatal diabetes

Feb. 26, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...